COMT inhibitor

COMT inhibitor

Catechol-o-methyltransferase inhibitor Neurology A drug that enhances the effectiveness of levodopa by blocking COMT, an enzyme that metabolizes levodopa before it reaches the brain; ↑ levodopa bioavailability in the brain results in steady and continuous dopaminergic stimulation, and more consistent and effective symptom relief in Parkinson's disease
References in periodicals archive ?
According to BIAL, ONGENTYS (opicapone) is a novel, once-daily, peripherally-acting, highly-selective COMT inhibitor proposed for use as adjunct therapy to levodopa in Parkinson's patients.
For example, the COMT inhibitor, tolcapone (Tasmar[R]), has been withdrawn from use in several countries (excluding the US) because it can increase liver problems by as much as 100%.
97 (carbidopa/ benefit of levodopa long-acting (Highly controlled- form (1,8) variable due to release) dose range) COMT inhibitor Augments Same side $310.
While the studies carried out in Europe have proved the effectiveness of this COMT inhibitor in L-dopa-induced hyperhomocysteinemia, no correlation has been demonstrated in studies conducted in the USA (2,22,24).
11) Tolcapone, a clinically approved COMT inhibitor for the treatment of PD, assists in managing problematic symptoms through maintenance of dopamine levels.
When the other available COMT inhibitor, entacapone (Comtan), is given as 200 mg with each dose of Sinemet, it reduces L-dopa peaks.
Many neurologists prefer prescribing levodopa and a COMT inhibitor in patients with severe disease, the guideline authors pointed out.
Tolcapone (Tasmar) is the first COMT inhibitor to be available and works both peripherally and centrally to allow a greater half-life of levodopa and dopamine.
Contract notice: Open-house-discount contracts for drugs with the drug combination levodopa / decarboxylase inhibitor / comt inhibitor (levodopa / carbidopa / entacapone) = atc n04ba03.
In advanced disease, motor complications can also be managed by augmenting levodopa therapy with a dopamine agonist, MAO-B inhibitor, or COMT inhibitor (7,8) (SOR: A).
Adding a dopamine agonist or a COMT inhibitor to the regimen of a patient who is already on levodopa can cause dyskinesia and hallucinations, particularly in advanced patients.
Side effects of COMT inhibitors include nausea, vomiting, diarrhoea and abdominal pain.